MRKR - Cancer Cell Therapy Focused Marker Therapeutics Announces Pipeline Prioritization | Benzinga
Marker Therapeutics Inc (NASDAQ: MRKR) announced it is restructuring its clinical programs and strategic prioritization of its multi-tumor associated antigen (multiTAA)-specific T cell product pipeline.
The company has prioritized MT-601 in chimeric antigen receptor (CAR) relapse patients with lymphoma.
The FDA cleared Marker's Investigational New Drug application for a Phase 1 trial to investigate MT-601 combined with first-line chemotherapy in patients with pancreatic cancer.
The clinical advancement of this multicenter study will be pending additional funding from non-dilutive sources.
In addition, the company reported a clinical update on the Phase 2 ...